Opinion|Videos|August 23, 2024
Other Trials and Emerging Data in EGFR-Mutant NSCLC Treatment: Anticipating the Future Treatment Landscape
Author(s)Martin Dietrich, MD, PhD, Wade Iams, MD
Medical oncologists discuss the overall research landscape in advanced EGFR-mutant NSCLC, highlighting exciting trials and emerging data in the evolving treatment space.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What other trials/emerging data are you excited about in this treatment space? How do you anticipate the future treatment landscape to evolve for EGFR-mutant NSCLC?
Advertisement
Related to this article
Helena A. Yu, MD, discusses the background of REZILIENT3 and her key takeaways on zipalertinib in EGFR exon 20-mutated NSCLC.
Adults in the US with previously treated locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations can now access sunvozertinib.
At the BIG10 CRC Summit, Mingjia Li, MD, outlined how pre-operative hemoglobin may signal treatment response in resectable NSCLC.
The therapeutic cancer vaccine OSE2101 combined with either docetaxel or nivolumab met the primary end point of 1-year overall survival in the Combi-TED trial.
The oral KRAS G12D inhibitor VS-7375 produced responses in pancreatic, colorectal, and lung cancers in the phase 1/2 TARGET-D 101 trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
Top Poster Takeaways for Prostate Cancer From 2026 ESMO Congress
2
INTerpath-001 Data Detail Survival, Subgroup, and Safety Findings in Melanoma
3
ctDNA Is Prognostic Regardless of Therapy in Cisplatin-Eligible MIBC
4
Pembrolizumab Plus Chemo Shows Encouraging Activity in NEPC
5